Grifols witnessed an acceleration in Q3 sales, driven by solid demand for plasma products, along with strong contributions from other divisions. Adjusted EBITDA also increased but the momentum was partly held back by higher R&D and SG&A expenses. After taking into consideration the increase in financial expenses, net earnings fell ~8%. Fortunately, given the low-interest rate environment, Grifols plans to refinance its existing debt of €5.3bn.
